Literature DB >> 8392157

Modulation of morphine-induced sensitization by endogenous kappa opioid systems in the rat.

R Spanagel1, T S Shippenberg.   

Abstract

Sensitization to both the motor stimulant and mesolimbic dopamine-releasing effects of morphine were studied in animals chronically treated with morphine and those that had received the kappa opioid receptor antagonist, nor-binaltorphimine (nor-BNI) prior to the commencement of morphine treatment. Rats were pretreated with either nor-BNI (30 micrograms; i.c.v.) or its vehicle and then received injections of morphine for 10 days. Locomotor activity and microdialysis studies were then conducted 3 and 30 days after termination of the chronic morphine treatment. In chronic morphine-treated rats, sensitization developed to both the motor stimulatory effects of morphine and the mesolimbic dopamine-releasing effects of this drug. Sensitization was observed 3 and 30 days after termination of morphine treatment. In animals pretreated with nor-BNI, sensitization to both the motoric and dopamine-releasing effects of morphine was significantly greater than that of chronic morphine-treated rats. These results suggest that endogenous kappa opioid systems play an important role in morphine-induced sensitization and that manipulations of these systems can markedly influence both its behavioral and neurochemical expression.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8392157     DOI: 10.1016/0304-3940(93)90329-j

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  23 in total

Review 1.  Kappa opioid antagonists: past successes and future prospects.

Authors:  Matthew D Metcalf; Andrew Coop
Journal:  AAPS J       Date:  2005-10-27       Impact factor: 4.009

Review 2.  Kappa-opioid ligands in the study and treatment of mood disorders.

Authors:  William A Carlezon; Cécile Béguin; Allison T Knoll; Bruce M Cohen
Journal:  Pharmacol Ther       Date:  2009-06-02       Impact factor: 12.310

3.  Abuse-related effects of µ-opioid analgesics in an assay of intracranial self-stimulation in rats: modulation by chronic morphine exposure.

Authors:  Ahmad A Altarifi; Kenner C Rice; S Stevens Negus
Journal:  Behav Pharmacol       Date:  2013-09       Impact factor: 2.293

4.  The atypical antidepressant mirtazapine attenuates expression of morphine-induced place preference and motor sensitization.

Authors:  Steven M Graves; Amanda L Persons; Jennifer L Riddle; T Celeste Napier
Journal:  Brain Res       Date:  2012-07-20       Impact factor: 3.252

5.  Differential effects on natural reward processing in rats after repeated heroin.

Authors:  Ewa Galaj; Ivonne Cruz; Jordan Schachar; Matthew Koziolek; Robert Ranaldi
Journal:  Psychopharmacology (Berl)       Date:  2013-04-23       Impact factor: 4.530

6.  Withdrawal from repeated morphine sensitizes mice to the striatal dopamine release enhancing effect of acute morphine.

Authors:  J Airio; M Attila; T Leikola-Pelho; L Ahtee
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-11       Impact factor: 3.000

Review 7.  Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.

Authors:  William A Carlezon; Andrew D Krystal
Journal:  Depress Anxiety       Date:  2016-10       Impact factor: 6.505

8.  Delta-opioid receptor antagonists prevent sensitization to the conditioned rewarding effects of morphine.

Authors:  Toni S Shippenberg; Vladimir I Chefer; Alexis C Thompson
Journal:  Biol Psychiatry       Date:  2008-10-31       Impact factor: 13.382

9.  Neuroplasticity in the mesolimbic system induced by natural reward and subsequent reward abstinence.

Authors:  Kyle K Pitchers; Margaret E Balfour; Michael N Lehman; Neil M Richtand; Lei Yu; Lique M Coolen
Journal:  Biol Psychiatry       Date:  2009-12-16       Impact factor: 13.382

10.  Strain differences in the rewarding and dopamine-releasing effects of morphine in rats.

Authors:  M Shoaib; R Spanagel; T Stohr; T S Shippenberg
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.